TECARTUS® can only be administered at an Authorized Treatment Center1

In ZUMA-2, TECARTUS was provided as a single-dose, one-time infusion followed by at least 7 days of on-site monitoring1-3

TECARTUS® treatment process. TECARTUS® treatment process.

Pinch to zoom

*A lymphodepleting chemotherapy regimen is administered on the 5th, 4th, and 3rd day before infusion of TECARTUS. After thawing, premedication is administered 30 minutes to 1 hour prior to infusion, then TECARTUS is infused into the patient.1

In the ZUMA-2 study, TECARTUS was delivered to treatment centers in a median of 15 days from leukapheresis1

Authorized Treatment Centers are independent facilities certified to dispense Kite CAR T therapies. Choice of an Authorized Treatment Center is within the sole discretion of the physician and patient. Kite does not endorse any individual treatment sites.

AR=adverse reaction; ATC=Authorized Treatment Center; CAR=chimeric antigen receptor; HCP=healthcare professional.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma – study protocol. N Engl J Med. 2020;1-47. 3. Jacobson CA, Farooq U, Ghobadi A. Axicabtagene ciloleucel, an anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: practical implications for the community oncologist. Oncologist. 2020;25(1):e138-e146.